Mitral Valve Replacement in Patients with Extreme Pulmonary Hypertension: Tertiary Center Experience of 680 Cases

Mohamed Alassal1*, Moataz Rezk1, Ehab Fawzy1, Ashraf Elnahas1, Basem Mofreh1, Ahmed Sobhi1, Hany Osman2, Mohamed Saffan1 and Mahmoud Elemam1

1Cardiothoracic Surgery Department, Benha University Hospitals, Egypt
2Damanhour National Medical Institute, Egypt

Submission: January 02, 2018; Published: January 31, 2018

*Corresponding author: Mohamed Alassal, Cardiothoracic Surgery Department, Faculty of Medicine, Benha University Hospitals, Egypt, Email: dmohamedabdelwahab@gmail.com

Abstract

Many forms of left-sided heart disease can be associated with pulmonary hypertension (PH-LHD) which typically indicates more advanced heart disease, more severe symptoms and worse prognosis. Mitral valve disease, both insufficiency and stenosis, can lead to the downstream development of PH. Current guidelines suggest that the most effective therapy for severe mitral valve disease (stenosis and/or regurgitation) is surgical intervention, yet in some cases, the operative outcome bordered by high perioperative risks. Patients and methods: Data for this study included 680 cases of adult patients underwent first-time mitral valve replacement. All patients of the study were divided into 2 groups: those who had PASP 50-80mmHg categorized as severe pulmonary hypertension= (group I) and those who had PASP above 80mmHg Categorized as extreme PH= (group II).

Results: Echo-cardiographic data revealed that 60.3% (410/680) of patients had signs of mitral stenosis, 25% (170/680) had mitral regurgitation while 14.7% (100/680) had double mitral valve pathology (MS and MR). 76 patients (11.2%) had less than moderate TR, 132 (19.4%) had moderate TR and 472 (69.4%) had severe TR. Most of mortality in both groups occurs during the first post-operative week and occurred due to hemodynamic instability and acute heart failure. It was 3.7% (20/540) in group I and 14.3% (20/140) in group II with a marked rise in this rate between patients of group II (p=0.03). 12 cases out of the 20 (60%) of mortality of group I were above fifty years old and 16 cases out of the 20 cases of mortality of group II (80%) were above fifty years old and the statistical analysis revealed that increased age with the severity of pulmonary hypertension increase the rate of mortality (p=0.031).

Conclusion: Early referral of cases of mitral valve disease with PH to surgery once indicated to avoid increased operative risk secondary to long standing PHT. Mitral valve replacement (MVR) with severe PHT could be done with less risk when surgery offered at proper time with management strategy to avoid pulmonary hypertensive events.

Keywords: Rheumatic valve disease; Mitral stenosis; Pulmonary hypertension; Left sided heart disease

Introduction

In developing countries like in our country “Egypt”; rheumatic fever and rheumatic heart disease are bigger problems than ever. It was estimated recently that worldwide 15.6 million people have rheumatic heart disease and that there are 470,000 new cases of rheumatic fever and 233,000 deaths attributable to rheumatic fever or rheumatic heart disease each year. The actual numbers are likely to be higher in developing countries because almost all these numbers and statistics come from developing countries [1]. Many forms of left-sided heart disease can be associated with pulmonary hypertension (PH-LHD) which typically indicates more advanced heart disease, more severe symptoms and worse prognosis [2,3]. Pulmonary hypertension (PH) due to left-sided heart disease (LHD), classified by the World Health Organization as Group 2 (WHO 2), is secondary to left ventricular (LV) systolic dysfunction, LV diastolic dysfunction, or valvular heart disease (VHD) [4]. The principle insult in this class of PH is elevated left ventricular end diastolic pressure (LVEDP and/or left atrial pressures), which is transmitted to the pulmonary vasculature, raising pulmonary artery pressure [5]. Mitral valve disease, both insufficiency and stenosis, can lead to the downstream development of PH. Elevated PAP has long been recognized as a complication of mitral stenosis (MS) [6]. In mitral regurgitation it is dependent on the valvular abnormality and chronicity. Barbieri et al. [7] demonstrated that...
Pulmonary hypertension (PHT) has been considered a mortality risk factor in cardiac surgical patients found in 15–60% of patients who have mitral valve disease. Longstanding PHT increases the after load on the right ventricle, leading to hypotrophy and eventually, core-pulmonale [9].

The development of PH is often an indication for mitral valve (MV) or atrioventricular (AV) intervention, but has also been well documented to be a procedural risk factor [10]. Guideline-directed pharmacologic treatment for the underlying heart failure with reduced EF (HFrEF) and heart failure with preserved EF (HFpEF); diuretics, vasodilators, and neuro-hormonal antagonists. In addition, patients should be considered for mechanical support and resynchronization therapy when appropriate. Targeted therapies for PH-LHD are lacking, showing only limited benefit in symptomatic improvement without affecting clinical survival [11]. In developing countries, even young patients can present with a very advanced stage of valvular heart disease. The life expectancy of these patients is much lower than the national average. Almost negligible information is available from developing countries [6]. All the major studies are from the developed world. In the absence of perfect data, we will build our case using available evidence. The aim of our study is to find a strategy to improve outcome after mitral valve replacement in patients with severe and extreme PHT in our country.

Patients and Methods

Data for this study were obtained from the patients’ medical records in Banha University Hospital and others during the period (Jan 2010 to Dec 2016) and included 680 cases of adult patients underwent first-time mitral valve replacement. Patients with multi-valvular diseases were excluded as well as patients with ischemic heart diseases and patients with congenital heart disease past history of open heart surgeries.

All patients of the study were divided into 2 groups: those who had PASP 50-80mmHg categorized as severe pulmonary hypertension=group I and those who had PASP above 80mmHg Categorized as extreme PH=group II. PASP values were obtained from Doppler echocardiography or Right heart catheter and calculated using the modified Bernoulli equation (4 x [tricuspid regurgitation jet velocity] 2+right atrial pressure) [9]. All patients of both groups were given sildenafil in a dose of 0.5mg/kg single dose in the morning of surgery (2hs before induction of anesthesia). During operative procedure we start to give all patients milrinone at a dose of 50mcg/kg loading over 10 minutes then 0.375-0.75mcg/Kg/min IV infusion before coming off bypass.

During the procedure all patients started anesthetic process, cannulation and conduction of bypass, surgical procedure in the form of mitral valve replacement with tricuspid valve repair for cases with moderate and severe TR, weaning from heart-lung machine and patient transfer to the intensive care unit. Total bypass time and aortic cross clamp time was calculated in the two groups. We have used hemo-filter for all cases from the beginning of bypass, with total fluid balance calculation. Patients underwent mitral valve replacement and PASP was measured post-operatively, one month, three months and six months post-operatively.

Statistical Analysis

Data were collected and compared afterward. The information was entered in a computer-designed format to facilitate analysis by using the SPSS 9.0 statistical program for Windows. Quantitative variables were expressed as mean±standard deviation (SD). Difference before and after the mitral valve replacement were evaluated. The significance of the differences was calculated by Wilcoxon test for the paired groupings. The results from group II were compared with those from group I Analysis was carried out by the χ² tests for qualitative variables. In all cases, the results were considered statistically significantly when P value less than 0.05.

Results

Table 1: Demographic data of our patients.

| Variable                        | Number | %   |
|---------------------------------|--------|-----|
| Age (years)[range]              | 53.1±9.7[40-65] |     |
| Gender:                         |        |     |
| Male (n)                        | 238    | 35  |
| Female (n)                      | 442    | 65  |
| NYHA functional class           |        |     |
| III (n)                         | 508    | 74.7|
| IV (n)                          | 172    | 25.3|
| Atrial fibrillation (n)         | 380    | 55.9|
| Right ventricular hypertrophy (n)| 200    | 29.4|
| Edema of lower extremities (n)  | 272    | 40  |
| Mitral valve pathology:         |        |     |
| Mitral stenosis (n)             | 410    | 60.3|
| Mitral regurgitation (n)        | 170    | 25  |
| Mitral stenosis and mitral regurgitation (n) | 100 | 14.7|

The age of our patients ranged between 25-65 years with a mean of 54.1±8.9 years. 35% of our patients (238/680) were females.
males while 65% (442/680) were females with a male to female ratio 1:1.9. In our study, 74.7% of our patients (508/680) were classified as NYHA class III while 25.3% (172/680) were classified as class IV. Of our patients 55.9% (380/680) had atrial fibrillation and were under treatment, 272 patients (40%) had lower limb edema and 200 patients had evidence of right ventricular hypertrophy (29.4%) (Table 1).

Echocardiographic data revealed that 60.3% (410/680) of patients had signs of mitral stenosis and 25% (170/680) had mitral regurgitation while 14.7% (100/680) had double mitral valve pathology (MS and MR). 76 patients (11.2%) had less than moderate TR, 132 (19.4%) had moderate TR and 472 (69.4%) had severe TR. Patients of both groups underwent Echo examination and in group I (severe PHT) PASP ranged between 55-80mmHg with a mean of 63.5±18.1mmHg; left atrial diameter (LAD) ranged between 42-63mm with a mean of 52.3±10.3mm; left ventricular end diastolic diameter (LVDd) ranged between 40-70mm with a mean of 53.1±8.2mm and ejection fraction (EF%) ranged between 50-65% with a mean of 56.4±7.1%. Patients in group II (extreme PHT) PASP ranged between 85-110mmHg with a mean of 90.3±10.6mmHg; left atrial diameter ranged between 45-72mm with a mean of 56.1±12.4mm; left ventricular end diastolic diameter (LVDd) ranged between 55-74mm with a mean of 63.3±9.7mm and ejection fraction (EF%) ranged between 45-73% with a mean of 48.4±6.0% (Table 2).

| Variable | Severe PHT | Extreme PHT | P |
|----------|------------|-------------|---|
| **PASP (mmHg)** | 63.5±18.1 [55-80] | 42.3±11.6 [40-65] | 0.001 |
| **LAD (mm)** | 42.1±12.3 [38-55] | 39.5±9.3 [37-48.1] | 0.001 |
| **LVDd (mm)** | 53.1±8.2 [40-70] | 38.3±5.1 [39-63] | 0.038 |
| **LVEF (%)** | 56.4±7.1 [50-65] | 42.4±1.1 [45-76] | 0.254 |

| Variable | Severe PHT | Extreme PHT | P |
|----------|------------|-------------|---|
| **Perfusion time (min)** | 128.5±11 (110-140) | 150±14 (120-165) | 0.001 |
| **Cross-clamp time (min)** | 85±9 (70-110) | 110±12 (90-120) | 0.001 |
| **Failure to wean** | 20 (3.7%) | 14 (10%) | 0.1 |
| **PH criss in ICU** | 10 (1.3%) | 10 (7.14%) | 0.01 |
| **Readmission within 30 days** | 40 (7.4%) | 18 (12.9%) | 0.26 |
| **30 days mortality (%)** | 20 (3.7%) | 20 (14.3%) | 0.03 |

PASP: Pulmonary Arterial Systolic Pressure; LAD: Left Atrial Diameter; LVDd: Left Ventricular End-Diastolic Diameter; LVEF: Left Ventricular Ejection Fraction

### Operative Data

Cross clamp time in group I, it ranged between 70-110min with a mean of 85±9min while in group II it ranged between 75-120min with a mean of 95±11min and the statistical analysis revealed non-significant increase in the cross clamp time in group II (p=0.211). The cumulative perfusion time in group I ranged between 110-140min with a mean of 128.5±11min while in group II, the perfusion time ranged between 120-165min with a mean of with a mean of 150±14min and the statistical analysis revealed significant increase in the cumulative perfusion time in group II than group I (p=0.001).

After completion of the surgical procedure and starting to wean from the heart lung machine; we fail to wean only 1.85% (10/540) of cases of group I and 14.3% (20/140) of patients of group II. We re-established and resumed bypass again, adjust the blood chemistry (electrolytes, gases and pH) of patients, ensure connectivity of inotropic support and good ventilation and some patients required getting more fluid out using the hemo-filter due to apparent RV distension and impairment. After reaching a stable hemodynamic condition we start to wean again. The 10 cases of group (I) weaned successfully while 6 cases out of 20 in group (II) failed to wean from bypass and died on table and 12 cases weaned but left open chest due to RV impairment and distension (Table 3).

| Variable | PAP 50-680mmHg n=540 | PAP >80mmHg n=140 | P |
|----------|------------------------|---------------------|---|
| Perfusion time (min) | 128.5±11 (110-140) | 150±14 (120-165) | 0.001 |
| Cross-clamp time (min) | 85±9 (70-110) | 110±12 (90-120) | 0.001 |
| Failure to wean | 20 (3.7%) | 14 (10%) | 0.01 |
| PH criss in ICU | 10 (1.3%) | 10 (7.14%) | 0.01 |
| Readmission within 30 days | 40 (7.4%) | 18 (12.9%) | 0.26 |
| 30 days mortality (%) | 20 (3.7%) | 20 (14.3%) | 0.03 |

MPAP was found to decrease significantly over time as compared to baseline. Also, PVR decreased over time.
After weaning patients admitted to ICU and all under Inotrope, and pulmonary vasodilator (Milrinone) and norepinephrine with dobutamine infusion in some cases analgesics (Fentanyl) and we postponed weaning from mechanical ventilator until patients became hemodynamically stable and avoid pain and stress in order to prevent the rise in pulmonary pressure. We also gave the patients Sildenafil by NGT at a dose of 0.5mg/kg every 6-8 hours according to the hemodynamics. In ICU; ten patient of group I (10/540; 1.85%) and ten patients of group II (10/140; 7.14%) experienced pulmonary hypertensive crisis (severe hypotension and cyanosis), sudden arrestor persistent hemodynamic instability and they managed by cardiac resuscitation with increasing the dose of inotropic support and pulmonary vasodilators, complete sedation and oxygen therapy. The statistical analysis revealed occurrence of this crisis in a large scale in group II (p=0.01).

Forty patients out of group I (40/540; 28.6%) while 18 patients of group II (18/140; 12.9%) were readmitted to the operative theatre for different cases “bleeding, cardiac tamponade or sternal closure for cases with opened chest” and they were managed according to the cause and the statistical analysis revealed no significance between both groups (p=0.26). Mechanical ventilation hours in group I ranged between 12-76 hours and mean of 28±0.82 while in group II it ranged between 11-124 hours and mean of 56±1.3 and the statistical analysis revealed the increase in mechanical ventilation in group II than in group I (p=0.031). In group I, 6 cases out of 540 (1.1%) were readmitted to ICU after 2-5 days of ward transfer for cardiac or respiratory failure in addition to 10 cases for cardiac tamponade or pericardial hematoma. In group II; 4 cases out of 140 (2.9%) were readmitted to ICU after 2-5 days of ward transfer for cardiac or respiratory failure and another 4 cases (2.9%) for cardiac tamponade or pericardial effusion and 6 (4.3%) cases for management of rapid AF.

Cumulative ICU stay in days in group I ranged between 2-5 days with a mean of 3±0.5 days while in group II it ranged between 4-6 days with a mean of 5.5±0.5 days and the statistical analysis revealed increased ICU stay in group II than in group I (p=0.028). Most of mortality in both groups occurs during the first post-operative week and occurred due to hemodynamic instability and acute heart failure. It was 3.7% (20/540) in group I and 14.3% (20/140) in group II with a marked rise in this rate between patients of group II (p=0.03). 12 cases out of the 20 (60%) of mortality of group I were above fifty years old and 16 cases out of the 20 cases of mortality of group II (80%) were above fifty years old and the statistical analysis revealed that increased age with the severity of pulmonary hypertension increase the rate of mortality (p=0.031) (Table 4).

### Table 4: Relation between age of the patients and mortality in the study.

| Age of Patients | PAP 50-80mmHg n=20 | PAP >80mmHg n=20 | P |
|----------------|--------------------|------------------|----|
| Below 50 years | 40%(8/20) | 20%(4/20) | 0.031 |
| Above 50 years | 60%(12/20) | 80%(16/20) |       |

Ten cases out of the 20 (50%) of group I were have severe tricuspid regurgitation while 14 cases out of the 20 cases of group II (70%) have severe tricuspid regurgitation and the statistical analysis revealed that with increased severity of tricuspid regurgitation the mortality rate increases in cases with increased pulmonary pressure (p=0.028). It is important to know that the rate of complications and the mortality rise with the increase in pulmonary pressure up to 90mmHg (cut-off value) were there was no marked change in these rates.

### Follow-up ECHO Examination

Echocardiographic examination performed in the follow-up period at the end of first week post-operative, one, three and six post operative months. Patients of group I (severe PHT) the statistical analysis revealed that in the early and late follow-up showed marked decrease in the pulmonary artery pressure PASP ranged between 35-65mmHg with a mean of 42.3±11.6mmHg with significant reduction in the PASP (p=0.001). Also, the increased in the period between the diagnosis of the lesion and the time of operative procedure decreased the reverse of the rise in pulmonary pressure. The statistical analysis revealed that in the early follow-up period there was no marked change in Left Atrial Dimentions (LAD) while in the late follow-up LAD ranged between 37-48.1mm with a mean of 39.6±9.3mm with good reduction in LAD (p=0.001).

Also, the statistical analysis revealed that in the early follow-up period there was no marked change in LVDd (left ventricular diastolic dimension) while in the late follow-up LVDd ranged between 32-45mm with a mean of 38.3±5.1mm with a significant decrease in the LVDd as a result of reduction in the left ventricular mass (p=0.038). In addition, ejection fraction (EF%) at six months follow-up ranged between 45-78% with a mean of 42.1±4.1% and the statistical analysis revealed no significant change in the EF of group I between preoperative values and the follow-up values even at the end of follow-up (six months, p=0.254).

Patients of group II (extreme PHT) the statistical analysis revealed that in the early follow-up period there was also significant decrease in PASP in comparison to the preoperative measurements but with severe hypertension in many cases where PASP ranged between 45-78mmHg with mean of 62±10mmHg while in the 6-month follow-up PASP ranged between 40-70mmHg with mean of 55±8mmHg with significant reduction in the PASP (p=0.01). The statistical analysis revealed that in the early follow-up period there was no marked change in LAD while in the late follow-up LAD ranged between 37-63mm with a mean of 39.6±9.3mm with significant reduction in the LAD (p=0.01).

Also, the statistical analysis revealed that in the early follow-up period there was no marked change in LVDd while in the late follow-up LVDd ranged between 39-63mm with a mean of
40.3±6.3mm with a significant decrease in the LVDd as a result of reduction in the left ventricular mass (p=0.025). As well as, ejection fraction (EF%) at six months follow-up ranged between 45-78% with a mean of 55.7±5.3% and the statistical analysis revealed no significant change in the ejection fraction of group I between preoperative values and the follow-up values even at the end of follow-up (six months, p=0.31).

Discussion

Pulmonary arterial hypertension, defined as a mean pulmonary arterial pressure greater than 25mmHg at rest or greater than 30mmHg during exercise [12]. According to this definition, all our patients in this study have pulmonary hypertension at presentation. Throughout the 40 years over which surgical correction has been carried out, peri-operative mortality in mitral valve surgeries has decreased from 12.5% in the late 1950s to 6% in the 1960s, and to below 0.5% today. This major improvement in survival appears to be a reflection of both better operative technique and better post-operative care.

Some studies demonstrated in their work, 10% to 41.8% of patients developed pulmonary hypertension with mitral valve disease in varying degrees. Also, an interesting reference in the work of some authors, who demonstrated that in a number of patients with rheumatic mitral valve disease even with severe hypertension pre-operatively, had a good post-operative course, and found no relationship between pulmonary pressures pre-operatively. Enter [9] and his colleagues in their study have observed comparable outcomes between patients who have severe PHT and those without evidence of PHT and their results suggested that the degree of PHT may be an important consideration when calculating risk for postoperative mortality.

Recent series suggest that PHT should be included in the STS risk score [13]. However, in multivariate analyses, potential confounders (e.g., chronic obstructive pulmonary disorder) in PHT patients undergoing MVS may have exaggerated the mortality risk [14]. Ghoreishi et al. [15] reported a hospital mortality of 12% in patients underwent mitral valve surgery with severe PHT and they concluded that referral for MVS should be considered for patients who have PASP 40mm Hg or more lead to increased surgical risk.

Galie et al. [16], investigate the use of Phosphodiesterase type 5 inhibitors in PAH include sildenafil, tadalafil, and vardenafil. These agents have been shown in clinical trials to improve six-minute walk distance and hemodynamics. In our study, sildenafil was given as a routine medication for all cases with high pulmonary artery pressure; we found 66 % of the total cases to have no significant reduction in PAP before taking surgical repair. In literatures concerned about sildenafil found that, mid-term oral sildenafil therapy led to insignificant improvement in pulmonary hemodynamics, functional class and/or exercise tolerance [17,18]. So, in our study we assumed that there was insignificant reduction in post operative PASP with the use of pre and postoperative sildenafil and we think that the surgical correction alone is the main factor in reduction of postoperative PASP.

Age also was found to be a significant and independent predictor of surgical mortality and morbidity at early, mid and late follow up in our group of patients as same as other studies done by Simonneau et al. [12]. Secondary prophylaxis has been proved to be cost-effective and practical even in the poorest countries. For more than 20 years, the World Health Organization has recommended secondary prophylaxis, most effectively delivered within a coordinated program using a registry of patients, as the first priority for the control of rheumatic heart disease. Yet most developing countries still do not have effective secondary-prophylaxis programs [19-23].

Conclusion

Mitrval valve replacement (MVR) with severe PHT could be done with less risk when surgery offered at proper time with management strategy to avoid pulmonary hypertensive events.

Recommendation

We recommend Surgery should be performed in the younger patient and probably before structural changes in the myocardium or pulmonary vasculature have occured. Early referral of cases of mitral valve disease with PHT to surgery once indicated to avoid increased operative risk secondary to long standing PHT. In addition; the administration of milrinone as a pulmonary vasodilator from the start of surgical procedure as well as during ICU stays in cases of severe and extreme PHT. Also, administration of sildenafil preoperatively and continued postoperatively for six months orally in cases of severe and extreme PHT.

Acknowledgement

The authors would like to acknowledge all the medical and nursing staff who has contributed to the data collection. Also we would like to thank cardiac surgeons and cardiologists who contributed in patients’ management and we would like to thanks the research center’s staff for their contribution to this research and for their assistance with revising, and their contribution to conception, design and processing of this project.

References

1. Carpentis JR (2007) Rheumatic heart disease in developing countries. N Engl J Med 357(5): 439-441.
2. Vachiéry JL, Adir Y, Barberà JA, Champion H, Coghlan JC, et al. (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(25): D100-D108.
3. Maeder MT, Schoch OD, Kleiner R, Joerg L, Weilenmann D (2017) Pulmonary hypertension associated with left-sided heart disease. Swiss Med Wkly 147: w14395-w14407.
4. Fang JC, DeMarco T, Givertz MM, Borlaug BA, Lewis GD, et al. (2012) World health organization pulmonary hypertension group 2: pulmonary hypertension due to left heart disease in the adult-a summary statement from the pulmonary hypertension council of the international society for heart and lung transplantation. J Heart Lung Transplant 31(9): 913-933.
5. Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, et al. (2014) Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest 145(5): 1064-1070.
6. Kaple RK, Horn EM (2015) Pulmonary hypertension due to valvular heart disease: Aortic and Mitral. Adv Pul Hypert 14(2): 95-101.
7. Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Asterinos JF, et al. (2011) Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study. Eur Heart J 32(6): 751-759.
8. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, et al. (2014) 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg 147(2): 2440-2492.
9. Enter DH, Zaki A, Duncan BE, Kruse J, Andrei A, et al. (2016) A contemporary analysis of pulmonary hypertension in patients undergoing mitral valve surgery: Is this a risk factor? J Thorac Cardiovasc Surg 151(5): 1288-1299.
10. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, et al. (2012) Guidelines on the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J Cardiothorac Surg 42(4): S1-S44.
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16): e240-e327.
12. Simonneau G, Robbins IM, Beghetti M, Channick RN, Dekroix M, et al. (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(1): S43-S54.
13. Kennedy JL, Lapar DJ, Kern JA, Kron LL, Bergin JD, et al. (2013) Does the society of thoracic surgeons risk score accurately predict operative mortality for patients with pulmonary hypertension? J Thorac Cardiovasc Surg 146(3): 631-637.
14. Chan V, Ahnari A, Ruel M, Elmistekawy E, Hynes M, et al. (2014): Perioperative deaths after mitral valve operations may be overestimated by contemporary risk models. Ann Thorac Surg 98(2): 605-610.
15. Ghoreishi M, Evans CF, DeFilippi CR, Hobbs G, Young CA, et al. (2011) Pulmonary hypertension adversely affects short- and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. J Thorac Cardiovasc Surg 142(6): 1439-1452.
16. Galík N, Humbert M, Vachiery JL, Gibbs S, Lang I, et al. (2016) 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Rev Esp Cardiol 37(1): 67-119.
17. Choudhary SK, Talwar S, Arian B (2016) Choice of prosthetic heart valve in a developing country. Heart Asia 8(1): 65-72.
18. Toor D, Sharma N (2017) T cell subsets: an integral component in pathogenesis of rheumatic heart disease. Immunol Res doi: 10.1007/s12026-017-8978-z.
19. Chiang YP, Chikte J, Mosłowski AJ, Itagaki S, Adams DH, et al. (2014) Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA 312(13): 1323-1329.
20. Rahimtoola SH (2010) Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 55(22): 2413-2426.
21. Chan V, Lam BK, Rubens FD, Hendry P, Masters R, et al. (2012) Long-term evaluation of biological versus mechanical prosthetic use at reoperative aortic valve replacement. J Thorac Cardiovasc Surg 144(1): 146-151.
22. Musuku J, Lungu JC, Machila E, Jones C, Colin L (2017) Epidemiology of pharyngitis as reported by Zambian school children and their families: implications for demand-side interventions to prevent rheumatic heart disease. BMC Infect Dis 17(1): 473.
23. Huang G, Rahimtoola SH (2011) Prosthetic heart valve. Circulation 123(22): 2602-2605.